Abstract
Endostatin is an endogenous inhibitor of angiogenesis and has been shown to exhibit potent inhibitory activity in certain mice tumor models. In this study, a treatment strategy of combining recombinant human endostatin (rhEndostatin) and chemotherapeutics was implemented to evaluate the therapeutic efficacy of rhEndostatin against solid tumors. The antitumor effect of rhEndostatin in combination with several chemotherapeutic drugs, e.g., 5-fluorouracil, cyclophosphamide, methotrexate, and mitomycin C, on human QGY liver tumor and mice H22 liver tumor was compared with that of rhEndostatin treatment alone. The results showed that the combination of rhEndostatin and chemotherapeutic drugs resulted in a more potent inhibition of tumor growth. The potential advantages of rhEndostatin plus tumor chemotherapy provide a basis for further clinical trials of rhEndostatin.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acid Sequence
-
Animals
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols*
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Endostatins / administration & dosage
-
Endostatins / chemistry
-
Endostatins / pharmacology
-
Endostatins / therapeutic use*
-
Humans
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / pathology
-
Male
-
Mice
-
Mice, Inbred BALB C
-
Molecular Sequence Data
-
Neoplasm Transplantation
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / chemistry
-
Recombinant Proteins / pharmacology
-
Recombinant Proteins / therapeutic use*
-
Xenograft Model Antitumor Assays*
Substances
-
Antineoplastic Agents
-
Endostatins
-
Recombinant Proteins